You are here: Industry Insights > multiple sclerosis

News List

New data at AAN reinforce clinical benefit of Roche's OCREVUS™ (ocrelizumab) for relapsing and prima worldpharmanews
April 28, 2017
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from the OCREVUS™ (ocrelizumab) clinical trial programmes will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts.
Research moves closer to unraveling mystery cause of multiple sclerosis worldpharmanews
April 25, 2017
A new study has made a major new discovery towards finding the cause of multiple sclerosis (MS), potentially paving the way for research to investigate new treatments.
First ever biosimilar of interferon beta-1a approved in Russia cphi-online
March 07, 2017
Represents Biocad's third authorized medicine for the treatment of relapsing-remitting multiple sclerosis.
Perrigo to sell Tysabri royalty stream to Royalty Pharma for up to $2.85 billion firstwordpharma
February 28, 2017
Perrigo announced Monday that it signed a definitive agreement to divest its rights to the royalty stream from global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma in a deal worth as much as $2.85 billion.
Apitope’s Phase II multiple sclerosis trial a success europeanpharmaceuticalreview
February 23, 2017
Apitope announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis.
Cladribine tablets significantly reduced brain atrophy in patients with multiple sclerosis worldpharmanews
February 10, 2017
Merck, a leading science and technology company, today announced the publication of the results of a post hoc analysis of the Phase III CLARITY study in Multiple Sclerosis Journal.
RedHill Biopharma announces allowance of a patent in Japan supporting RHB-104 for multiple sclerosis pharmaasia
January 13, 2017
RedHill has received from the Japan Patent Office a Notice of Allowance for a new patent covering RHB-104 for multiple sclerosis (MS), expected to be valid until 2032, once granted.

Previous page 1 2 3 4 5 6 Next page